Metraipolis › archive › dc_85d2e4a36e32

Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42521925
DOI
10.1186/s43046-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-10-17T11:27:49.542Z
SHA-256 of the archived text
54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c
Stable URL of this page
https://metraipolis.com/documento/dc_85d2e4a36e32

How to cite

Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925 — Europe PMC (en), https://europepmc.org/article/MED/42521925 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_85d2e4a36e32 (Metraipolis archive dc_85d2e4a36e32, sha256 54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c)
BibTeX
@misc{dc85d2e4a36e32,
  title = {Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42521925},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_85d2e4a36e32; sha256 54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42521925. Agents can read the archived copy with the MCP tool read_document.